By Jennifer Ahlstrom | Posted - Jun 29th, 2017





Clinical Trial: Antibody Phase I Study Targeting CD-352 for Relapsed/Refractory Myeloma Patients

A Phase I clinical trial testing an antibody that targets CD-352 is open for multiple myeloma patients who have had two lines of treatment including an immunomodulator and proteasome inhibitor. This study is in conjunction with Seattle Genetics and is open at 7 sites throughout the U.S. To learn more, listen to Dr. Damian Green discuss this study:

Learn more about this clinical trial here: CD-352 Clinical Trial

Jennifer Ahlstrom
About the Author

Jennifer Ahlstrom - Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.


Add a Comment



Thanks to our Myeloma Crowd Community sponsors:

.                         .       .